MedTrace Logo

High-Dose Dual Therapy for H. Pylori Eradication (RETRO-HP Study)

NCT07121205 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2025-08-13

No results posted yet for this study

Summary

Background:

High-dose dual therapy (HDDT) has emerged as a potential first-line treatment for Helicobacter pylori infection, but its efficacy and safety across different regimens and populations remain unclear. This study aimed to compare real-world outcomes of various HDDT protocols and identify factors influencing treatment failure.

Methods:

A multicenter retrospective analysis was conducted using data from 15 medical centers (January 2022-January 2025). Patients received one of four HDDT regimens: vonoprazan-amoxicillin for 10 days (VA-10) or 14 days (VA-14), esomeprazole-amoxicillin (EA), or tegoprazan-amoxicillin (TA). Primary outcomes included eradication rates (modified intention-to-treat analysis) and adverse events.

Conditions

  • HELICOBACTER PYLORI INFECTIONS

Interventions

OTHER

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Liyueyue

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2025-07-01
Completion
2025-07-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07121205 on ClinicalTrials.gov